Nutriband Inc. (NTRB)

$3.9739

+0.01 (+0.35%)
Rating:
Recommendation:
-
Symbol NTRB
Price $3.9739
Beta -0.226
Volume Avg. 0.06M
Market Cap 31.009M
Shares () -
52 Week Range 2.409949-10.566038
1y Target Est -
DCF Unlevered NTRB DCF ->
DCF Levered NTRB LDCF ->
ROE -60.98% Strong Sell
ROA -63.80% Strong Sell
Operating Margin -
Debt / Equity 9.47% Neutral
P/E -
P/B 3.21 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NTRB news


Mr. Sean Gallagher
Healthcare
Biotechnology
NASDAQ Capital Market

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.